ICON PLC (ICLR)vsThermo Fisher Scientific Inc (TMO)
ICLR
ICON PLC
$169.31
+2.18%
HEALTHCARE · Cap: $12.22B
TMO
Thermo Fisher Scientific Inc
$609.82
+1.10%
HEALTHCARE · Cap: $225.48B
Smart Verdict
WallStSmart Research — data-driven comparison
Thermo Fisher Scientific Inc generates 459% more annual revenue ($46.34B vs $8.29B). TMO leads profitability with a 15.0% profit margin vs 0.3%. ICLR appears more attractively valued with a PEG of 0.50. TMO earns a higher WallStSmart Score of 60/100 (C+).
ICLR
Buy51
out of 100
Grade: C-
TMO
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+61.0%
Fair Value
$341.51
Current Price
$169.31
$172.20 discount
Margin of Safety
-76.7%
Fair Value
$345.06
Current Price
$609.82
$264.76 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Mega-cap, among the largest globally
Generating 1.7B in free cash flow
Areas to Watch
1.2% revenue growth
Distress zone — elevated risk
ROE of 0.7% — below average capital efficiency
0.3% margin — thin
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ICLR
The strongest argument for ICLR centers on PEG Ratio, Price/Book. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bull Case : TMO
The strongest argument for TMO centers on Market Cap, Free Cash Flow. Revenue growth of 10.5% demonstrates continued momentum.
Bear Case : ICLR
The primary concerns for ICLR are Revenue Growth, Altman Z-Score, Return on Equity. A P/E of 247.4x leaves little room for execution misses. Thin 0.3% margins leave little buffer for downturns.
Bear Case : TMO
The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ICLR carries more volatility with a beta of 1.20 — expect wider price swings.
TMO is growing revenue faster at 10.5% — sustainability is the question.
TMO generates stronger free cash flow (1.7B), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TMO scores higher overall (60/100 vs 51/100) and 10.5% revenue growth. ICLR offers better value entry with a 61.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ICON PLC
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
ICON Public Limited Company, a clinical research organization, provides outsourced marketing and development services in Ireland, the rest of Europe, the United States and internationally. The company is headquartered in Dublin, Ireland.
Thermo Fisher Scientific Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?